Heparin, also known as unfractionated heparin (UFH), is medication which is used as an anticoagulant (blood thinner). Specifically it is used to treat and prevent deep vein thrombosis, pulmonary embolism, and arterial thromboembolism. It is also used in the treatment of heart attacks and unstable angina. It is given by injection into a vein. Other uses include inside test tubes and kidney dialysis machines.
|Biological half-life||1.5 hours|
|Chemical and physical data|
|Molar mass||12000–15000 g/mol|
|(what is this?)|
Common side effects include bleeding, pain at the injection site, and low blood platelets. Serious side effects include heparin induced thrombocytopenia. Greater care is needed in those with poor kidney function. Heparin appears to be relatively safe for use during pregnancy and breastfeeding. Heparin is a naturally occurring glycosaminoglycan.
The discovery of heparin was announced in 1916. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world, when used for prevention, is about 9.63 to 37.95 USD per month. In the United States it costs about 25 to 50 USD per month. A fractionated version of heparin, known as low molecular weight heparin is also available.
Heparin is a naturally occurring anticoagulant produced by basophils and mast cells. In therapeutic doses, it acts as an anticoagulant, preventing the formation of clots and extension of existing clots within the blood. While heparin does not break down clots that have already formed (unlike tissue plasminogen activator), it allows the body's natural clot lysis mechanisms to work normally to break down clots that have formed. Heparin is generally used for anticoagulation for the following conditions:
- Acute coronary syndrome, e.g., NSTEMI
- Atrial fibrillation
- Deep-vein thrombosis and pulmonary embolism
- Cardiopulmonary bypass for heart surgery
- ECMO circuit for extracorporeal life support
- Indwelling central or peripheral venous catheters
Heparin and its low-molecular-weight derivatives (e.g., enoxaparin, dalteparin, tinzaparin) are effective at preventing deep vein thromboses and pulmonary emboli in people at risk, but no evidence indicates any one is more effective than the other in preventing mortality.
A serious side-effect of heparin is heparin-induced thrombocytopenia (HIT), caused by an immunological reaction that makes platelets a target of immunological response, resulting in the degradation of platelets, which causes thrombocytopenia. This condition is usually reversed on discontinuation, and in general can be avoided with the use of synthetic heparins. Also, a benign form of thrombocytopenia is associated with early heparin use, which resolves without stopping heparin.
Two non-hemorrhagic side-effects of heparin treatment are known. The first is elevation of serum aminotransferase levels, which has been reported in as many as 80% of patients receiving heparin. This abnormality is not associated with liver dysfunction, and it disappears after the drug is discontinued. The other complication is hyperkalemia, which occurs in 5 to 10% of patients receiving heparin, and is the result of heparin-induced aldosterone suppression. The hyperkalemia can appear within a few days after the onset of heparin therapy. More rarely, the side-effects alopecia and osteoporosis can occur with chronic use.
As with many drugs, overdoses of heparin can be fatal. In September 2006, heparin received worldwide publicity when three prematurely born infants died after they were mistakenly given overdoses of heparin at an Indianapolis hospital.
This section needs additional citations for verification. (April 2017) (Learn how and when to remove this template message)
Heparin is contraindicated in those with risk of bleeding (especially in people with uncontrolled blood pressure, liver disease, and stroke), severe liver disease, or severe hypertension.
Antidote to heparinEdit
Protamine sulfate has been given to counteract the anticoagulant effect of heparin (1 mg per 100 units of heparin that had been given over the past four hours). It may be used in those who overdose on heparin or to reverse heparin's effect when it is no longer needed.
Heparin's normal role in the body is unclear. Heparin is usually stored within the secretory granules of mast cells and released only into the vasculature at sites of tissue injury. It has been proposed that, rather than anticoagulation, the main purpose of heparin is defense at such sites against invading bacteria and other foreign materials. In addition, it is observed across a number of widely different species, including some invertebrates that do not have a similar blood coagulation system. It is a highly sulfated glycosaminoglycan. It has the highest negative charge density of any known biological molecule.
In addition to the bovine and porcine tissue from which pharmaceutical-grade heparin is commonly extracted, it has also been extracted and characterised from:
The biological activity of heparin within species 6–11 is unclear and further supports the idea that the main physiological role of heparin is not anticoagulation. These species do not possess any blood coagulation system similar to that present within the species listed 1–5. The above list also demonstrates how heparin has been highly evolutionarily conserved, with molecules of a similar structure being produced by a broad range of organisms belonging to many different phyla.
In nature, heparin is a polymer of varying chain size. Unfractionated heparin (UFH) as a pharmaceutical is heparin that has not been fractionated to sequester the fraction of molecules with low molecular weight. In contrast, low-molecular-weight heparin (LMWH) has undergone fractionation for the purpose of making its pharmacodynamics more predictable. Often either UFH or LMWH can be used; in some situations one or the other is preferable.
Mechanism of actionEdit
Heparin binds to the enzyme inhibitor antithrombin III (AT), causing a conformational change that results in its activation through an increase in the flexibility of its reactive site loop. The activated AT then inactivates thrombin, factor Xa and other proteases. The rate of inactivation of these proteases by AT can increase by up to 1000-fold due to the binding of heparin. Heparin binds to antithrombin via a specific pentasaccharide sulfation sequence contained within the heparin polymer:
The conformational change in AT on heparin-binding mediates its inhibition of factor Xa. For thrombin inhibition, however, thrombin must also bind to the heparin polymer at a site proximal to the pentasaccharide. The highly negative charge density of heparin contributes to its very strong electrostatic interaction with thrombin. The formation of a ternary complex between AT, thrombin, and heparin results in the inactivation of thrombin. For this reason, heparin's activity against thrombin is size-dependent, with the ternary complex requiring at least 18 saccharide units for efficient formation. In contrast, antifactor Xa activity requires only the pentasaccharide-binding site.
This size difference has led to the development of low-molecular-weight heparins (LMWHs) and, more recently, to fondaparinux as pharmaceutical anticoagulants. LMWHs and fondaparinux target antifactor Xa activity rather than antithrombin activity, with the aim of facilitating a more subtle regulation of coagulation and an improved therapeutic index. The chemical structure of fondaparinux is shown above. It is a synthetic pentasaccharide, whose chemical structure is almost identical to the AT binding pentasaccharide sequence that can be found within polymeric heparin and heparan sulfate.
With LMWH and fondaparinux, the risk of osteoporosis and heparin-induced thrombocytopenia (HIT) is reduced. Monitoring of the activated partial thromboplastin time is also not required and does not reflect the anticoagulant effect, as APTT is insensitive to alterations in factor Xa.
Danaparoid, a mixture of heparan sulfate, dermatan sulfate, and chondroitin sulfate can be used as an anticoagulant in patients having developed HIT. Because danaparoid does not contain heparin or heparin fragments, cross-reactivity of danaparoid with heparin-induced antibodies is reported as less than 10%.
The effects of heparin are measured in the lab by the partial thromboplastin time (aPTT), one of the measures of the time it takes the blood plasma to clot. Partial thromboplastin time should not be confused with prothrombin time, or PT, which measures blood clotting time through a different pathway of the coagulation cascade.
Heparin is given parenterally because it is not absorbed from the gut, due to its high negative charge and large size. It can be injected intravenously or subcutaneously (under the skin); intramuscular injections (into muscle) are avoided because of the potential for forming hematomas. Because of its short biologic half-life of about one hour, heparin must be given frequently or as a continuous infusion. Unfractionated heparin has a half-life of about one to two hours after infusion, whereas LMWH has a half-life of four to five hours. The use of LMWH has allowed once-daily dosing, thus not requiring a continuous infusion of the drug. If long-term anticoagulation is required, heparin is often used only to commence anticoagulation therapy until an oral anticoagulant e.g. warfarin takes effect.
Natural degradation or clearanceEdit
Unfractionated heparin has a half-life of about one to two hours after infusion, whereas low-molecular-weight heparin's half-life is about four times longer. Lower doses of heparin have a much shorter half-life than larger ones. Heparin binding to macrophage cells is internalized and depolymerized by the macrophages. It also rapidly binds to endothelial cells, which precludes the binding to antithrombin that results in anticoagulant action. For higher doses of heparin, endothelial cell binding will be saturated, such that clearance of heparin from the bloodstream by the kidneys will be a slower process.
Native heparin is a polymer with a molecular weight ranging from 3 to 30 kDa, although the average molecular weight of most commercial heparin preparations is in the range of 12 to 15 kDa. Heparin is a member of the glycosaminoglycan family of carbohydrates (which includes the closely related molecule heparan sulfate) and consists of a variably sulfated repeating disaccharide unit. The main disaccharide units that occur in heparin are shown below. The most common disaccharide unit is composed of a 2-O-sulfated iduronic acid and 6-O-sulfated, N-sulfated glucosamine, IdoA(2S)-GlcNS(6S). For example, this makes up 85% of heparins from beef lung and about 75% of those from porcine intestinal mucosa.
Not shown below are the rare disaccharides containing a 3-O-sulfated glucosamine (GlcNS(3S,6S)) or a free amine group (GlcNH3+). Under physiological conditions, the ester and amide sulfate groups are deprotonated and attract positively charged counterions to form a heparin salt. Heparin is usually administered in this form as an anticoagulant.
- GlcA = β-D-glucuronic acid
- IdoA = α-L-iduronic acid
- IdoA(2S) = 2-O-sulfo-α-L-iduronic acid
- GlcNAc = 2-deoxy-2-acetamido-α-D-glucopyranosyl
- GlcNS = 2-deoxy-2-sulfamido-α-D-glucopyranosyl
- GlcNS(6S) = 2-deoxy-2-sulfamido-α-D-glucopyranosyl-6-O-sulfate
The three-dimensional structure of heparin is complicated because iduronic acid may be present in either of two low-energy conformations when internally positioned within an oligosaccharide. The conformational equilibrium is influenced by sulfation state of adjacent glucosamine sugars. Nevertheless, the solution structure of a heparin dodecasaccharide composed solely of six GlcNS(6S)-IdoA(2S) repeat units has been determined using a combination of NMR spectroscopy and molecular modeling techniques. Two models were constructed, one in which all IdoA(2S) were in the 2S0 conformation (A and B below), and one in which they are in the 1C4 conformation (C and D below). However, no evidence suggests that changes between these conformations occur in a concerted fashion. These models correspond to the protein data bank code 1HPN.
In the image above:
- A = 1HPN (all IdoA(2S) residues in 2S0 conformation) Jmol viewer
- B = van der Waals radius space filling model of A
- C = 1HPN (all IdoA(2S) residues in 1C4 conformation) Jmol viewer
- D = van der Waals radius space filling model of C
Either chemical or enzymatic depolymerisation techniques or a combination of the two underlie the vast majority of analyses carried out on the structure and function of heparin and heparan sulfate (HS).
The enzymes traditionally used to digest heparin or HS are naturally produced by the soil bacterium Pedobacter heparinus (formerly named Flavobacterium heparinum). This bacterium is capable of using either heparin or HS as its sole carbon and nitrogen source. To do so, it produces a range of enzymes such as lyases, glucuronidases, sulfoesterases, and sulfamidases. The lyases have mainly been used in heparin/HS studies. The bacterium produces three lyases, heparinases I (EC 184.108.40.206), II (no EC number assigned) and III (EC 220.127.116.11) and each has distinct substrate specificities as detailed below.
|Heparinase enzyme||Substrate specificity|
|Heparinase III||GlcNS/Ac(±6S)-GlcA/IdoA (with a preference for GlcA)|
The lyases cleave heparin/HS by a beta elimination mechanism. This action generates an unsaturated double bond between C4 and C5 of the uronate residue. The C4-C5 unsaturated uronate is termed ΔUA or UA. It is a sensitive UV chromophore (max absorption at 232 nm) and allows the rate of an enzyme digest to be followed, as well as providing a convenient method for detecting the fragments produced by enzyme digestion.
Nitrous acid can be used to chemically depolymerise heparin/HS. Nitrous acid can be used at pH 1.5 or at a higher pH of 4. Under both conditions, nitrous acid effects deaminative cleavage of the chain.
At both 'high' (4) and 'low' (1.5) pH, deaminative cleavage occurs between GlcNS-GlcA and GlcNS-IdoA, albeit at a slower rate at the higher pH. The deamination reaction, and therefore chain cleavage, is regardless of O-sulfation carried by either monosaccharide unit.
At low pH, deaminative cleavage results in the release of inorganic SO4, and the conversion of GlcNS into anhydromannose (aMan). Low-pH nitrous acid treatment is an excellent method to distinguish N-sulfated polysaccharides such as heparin and HS from non N-sulfated polysacchrides such as chondroitin sulfate and dermatan sulfate, chondroitin sulfate and dermatan sulfate not being susceptible to nitrous acid cleavage.
Detection in body fluidsEdit
Current clinical laboratory assays for heparin rely on an indirect measurement of the effect of the drug, rather than on a direct measure of its chemical presence. These include activated partial thromboplastin time (APTT) and antifactor Xa activity. The specimen of choice is usually fresh, nonhemolyzed plasma from blood that has been anticoagulated with citrate, fluoride, or oxalate.
Heparin was discovered by Jay McLean and William Henry Howell in 1916, although it did not enter clinical trials until 1935. It was originally isolated from canine liver cells, hence its name (hepar or "ήπαρ" is Greek for "liver"; hepar + -in).
McLean was a second-year medical student at Johns Hopkins University, and was working under the guidance of Howell investigating pro-coagulant preparations, when he isolated a fat-soluble phosphatide anticoagulant in canine liver tissue. In 1918, Howell coined the term 'heparin' for this type of fat-soluble anticoagulant. In the early 1920s, Howell isolated a water-soluble polysaccharide anticoagulant, which he also termed 'heparin', although it was different from the previously discovered phosphatide preparations. McLean's work as a surgeon probably changed the focus of the Howell group to look for anticoagulants, which eventually led to the polysaccharide discovery.
In the 1930s, several researchers were investigating heparin. Erik Jorpes at Karolinska Institutet published his research on the structure of heparin in 1935, which made it possible for the Swedish company Vitrum AB to launch the first heparin product for intravenous use in 1936. Between 1933 and 1936, Connaught Medical Research Laboratories, then a part of the University of Toronto, perfected a technique for producing safe, nontoxic heparin that could be administered to patients, in a saline solution. The first human trials of heparin began in May 1935, and, by 1937, it was clear that Connaught's heparin was a safe, easily available, and effective as a blood anticoagulant. Prior to 1933, heparin was available in small amounts, was extremely expensive and toxic, and, as a consequence, of no medical value.
- Test tubes, Vacutainers, and capillary tubes that use the lithium salt of heparin (lithium heparin) as an anticoagulant are usually marked with green stickers and green tops. Heparin has the advantage over EDTA of not affecting levels of most ions. However, the levels of ionized calcium may be decreased if the concentration of heparin in the blood specimen is too high. Heparin can interfere with some immunoassays, however. As lithium heparin is usually used, a person's lithium levels cannot be obtained from these tubes; for this purpose, royal-blue-topped (and dark green-topped) vacutainers containing sodium heparin are used.
- Heparin-coated blood oxygenators are available for use in heart-lung machines. Among other things, these specialized oxygenators are thought to improve overall biocompatibility and host homeostasis by providing characteristics similar to those of native endothelium.
- The DNA binding sites on RNA polymerase can be occupied by heparin, preventing the polymerase from binding to promoter DNA. This property is exploited in a range of molecular biological assays.
- Common diagnostic procedures require PCR amplification of a patient's DNA, which is easily extracted from white blood cells treated with heparin. This poses a potential problem, since heparin may be extracted along with the DNA, and it has been found to interfere with the PCR reaction at levels as low as 0.002 U in a 50 μL reaction mixture.
- Heparin has been used as a chromatography resin, acting as both an affinity ligand and an ion exchanger. Heparin’s specific affinity for VSV-G, a viral envelope glycoprotein often used to pseudotype retroviral and lentiviral vectors for gene therapy, allows it to be used for downstream purification of viral vectors.
Society and cultureEdit
Considering the animal source of pharmaceutical heparin, the numbers of potential impurities are relatively large compared with a wholly synthetic therapeutic agent. The range of possible biological contaminants includes viruses, bacterial endotoxins, transmissible spongiform encephalopathy (TSE) agents, lipids, proteins, and DNA. During the preparation of pharmaceutical-grade heparin from animal tissues, impurities such as solvents, heavy metals, and extraneous cations can be introduced. However, the methods employed to minimize the occurrence and to identify and/or eliminate these contaminants are well established and listed in guidelines and pharmacopoeias. The major challenge in the analysis of heparin impurities is the detection and identification of structurally related impurities. The most prevalent impurity in heparin is dermatan sulfate (DS), also known as chondroitin sulfate B. The building-block of DS is a disaccharide composed of 1,3-linked N-acetyl galactosamine (GalN) and a uronic acid residue, connected via 1,4 linkages to form the polymer. DS is composed of three possible uronic acid (GlcA, IdoA or IdoA2S) and four possible hexosamine (GalNAc, Gal- NAc4S, GalNAc6S, or GalNAc4S6S) building-blocks. The presence of iduronic acid in DS distinguishes it from chrondroitin sulfate A and C and likens it to heparin and HS. DS has a lower negative charge density overall compared to heparin. A common natural contaminant, DS is present at levels of 1–7% in heparin API, but has no proven biological activity that influences the anticoagulation effect of heparin.
In December 2007, the US Food and Drug Administration (FDA) recalled a shipment of heparin because of bacterial growth (Serratia marcescens) in several unopened syringes of this product. S. marcescens can lead to life-threatening injuries and/or death.
In March 2008, major recalls of heparin were announced by the FDA due to contamination of the raw heparin stock imported from China. According to the FDA, the adulterated heparin killed 81 people in the United States. The adulterant was identified as an "over-sulphated" derivative of chondroitin sulfate, a popular shellfish-derived supplement often used for arthritis, which was intended to substitute for actual heparin in potency tests.
2008 recall due to contaminationEdit
In March 2008, major recalls of heparin were announced by pharmaceutical companies due to a suspected and unknown contamination of the raw heparin stock imported from China. The contaminant was later found to be a compound called oversulfated chondroitin sulfate. The US Food and Drug Administration was quoted as stating at least 19 deaths were believed linked to a raw heparin ingredient imported from the People's Republic of China, and they had also received 785 reports of serious injuries associated with the drug’s use. According to the New York Times: 'Problems with heparin reported to the agency include difficulty breathing, nausea, vomiting, excessive sweating and rapidly falling blood pressure that in some cases led to life-threatening shock'.
Use in homicideEdit
In 2007, a nurse at Cedars-Sinai Medical Center mistakenly gave the 12-day-old twins of actor Dennis Quaid a dose of heparin that was 1,000 times the recommended dose for infants. The overdose allegedly arose because the labeling and design of the adult and infant versions of the product were similar. The Quaid family subsequently sued the manufacturer, Baxter Healthcare Corp., and settled with the hospital for $750,000. Prior to the Quaid accident, six newborn babies at Methodist Hospital in Indianapolis, Indiana, were given an overdose. Three of the babies died after the mistake.
In July 2008, another set of twins born at Christus Spohn Hospital South, in Corpus Christi, Texas, died after an accidentally administered overdose of the drug. The overdose was due to a mixing error at the hospital pharmacy and was unrelated to the product's packaging or labeling. As of July 2008[update], the exact cause of the twins' death was under investigation.
In March 2010, a two-year-old transplant patient from Texas was given a lethal dose of heparin at the University of Nebraska Medical Center. The exact circumstances surrounding her death are still under investigation.
Pharmaceutical-grade heparin is derived from mucosal tissues of slaughtered meat animals such as porcine (pig) intestines or bovine (cattle) lungs. Advances to produce heparin synthetically have been made in 2003 and 2008. In 2011, a chemoenzymatic process of synthesizing low molecular weight heparins from simple disaccharides was reported.
As detailed in the table below, the potential is great for the development of heparin-like structures as drugs to treat a wide range of diseases, in addition to their current use as anticoagulants.
|Disease states sensitive to heparin||Heparin's effect in experimental models||Clinical status|
|Acquired immunodeficiency syndrome||Reduces the ability of human immunodeficiency virus types 1 and 2 to adsorb to cultured T4 cells.||-|
|Adult respiratory distress syndrome||Reduces cell activation and accumulation in airways, neutralizes mediators and cytotoxic cell products, and improves lung function in animal models||Controlled clinical trials|
|Allergic encephalomyelitis||Effective in animal models||-|
|Allergic rhinitis||Effects as for adult respiratory distress syndrome, although no specific nasal model has been tested||Controlled clinical trial|
|Arthritis||Inhibits cell accumulation, collagen destruction and angiogenesis||Anecdotal report|
|Asthma||As for adult respiratory distress syndrome, however, it has also been shown to improve lung function in experimental models||Controlled clinical trials|
|Cancer||Inhibits tumour growth, metastasis and angiogenesis, and increases survival time in animal models||Several anecdotal reports|
|Delayed-type hypersensitivity reactions||Effective in animal models||-|
|Inflammatory bowel disease||Inhibits inflammatory cell transport in general, no specific model tested||Controlled clinical trials|
|Interstitial cystitis||Effective in a human experimental model of interstitial cystitis||Related molecule now used clinically|
|Transplant rejection||Prolongs allograft survival in animal models||-|
- indicates no information available
As a result of heparin's effect on such a wide variety of disease states, a number of drugs are indeed in development whose molecular structures are identical or similar to those found within parts of the polymeric heparin chain.
|Drug molecule||Effect of new drug compared to heparin||Biological activities|
|Heparin tetrasaccharide||Nonanticoagulant, nonimmunogenic, orally active||Antiallergic|
|Pentosan polysulfate||Plant derived, little anticoagulant activity, anti-inflammatory, orally active||Anti-inflammatory, antiadhesive, antimetastatic|
|Phosphomannopentanose sulfate||Potent inhibitor of heparanase activity||Antimetastatic, antiangiogenic, anti-inflammatory|
|Selectively chemically O-desulphated heparin||Lacks anticoagulant activity||Anti-inflammatory, antiallergic, antiadhesive|
- Heparin Sodium injection Archived 2013-09-05 at the Wayback Machine.
- heparin. In: Lexi-Drugs Online [database on the Internet]. Hudson (OH): Lexi-Comp, Inc.; 2007 [cited 2/10/12]. Available from: http://online.lexi.com Archived 2012-02-15 at the Wayback Machine.. subscription required to view.
- "Heparin Sodium". The American Society of Health-System Pharmacists. Archived from the original on 27 January 2016. Retrieved 1 January 2016.
- "Heparin (Mucous ) Injection BP - Summary of Product Characteristics (SPC) - (eMC)". www.medicines.org.uk. September 2016. Archived from the original on 20 December 2016. Retrieved 15 December 2016.
- McClatchey, Kenneth D. (2002). Clinical Laboratory Medicine. Lippincott Williams & Wilkins. p. 662. ISBN 9780683307511. Archived from the original on 2017-09-10.
- "Heparin Pregnancy and Breastfeeding Warnings". drugs.com. Archived from the original on 27 January 2016. Retrieved 15 January 2016.
- Li, Jie Jack; Corey, E. J. (2013). Drug Discovery: Practices, Processes, and Perspectives. John Wiley & Sons. p. 189. ISBN 9781118354469. Archived from the original on 2017-09-10.
- "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016.
- "Heparin". International Drug Price Indicator Guide. Retrieved 8 December 2016.
- Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. X. ISBN 9781284057560.
- Rietschel, Robert L.; Fowler, Joseph F.; Fisher, Alexander A. (2008). Fisher's Contact Dermatitis. PMPH-USA. p. 142. ISBN 9781550093780. Archived from the original on 2017-09-10.
- Guyton, A. C.; Hall, J. E. (2006). Textbook of Medical Physiology. Elsevier Saunders. p. 464. ISBN 0-7216-0240-1.
- Agnelli G, Piovella F, Buoncristiani P, et al. (1998). "Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery". N Engl J Med. 339 (2): 80–5. doi:10.1056/NEJM199807093390204. PMID 9654538.
- Bergqvist D, Agnelli G, Cohen AT, et al. (2002). "Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer". N Engl J Med. 346 (13): 975–980. doi:10.1056/NEJMoa012385. PMID 11919306. Archived from the original on 2008-10-25.
- Handoll HHG, Farrar MJ, McBirnie J, Tytherleigh-Strong G, Milne AA, Gillespie WJ; Farrar; McBirnie; Tytherleigh-Strong; Milne; Gillespie (2002). Handoll, Helen HG, ed. "Heparin, low molecular weight heparin and physical methods for preventing deep vein thrombosis and pulmonary embolism following surgery for hip fractures". Cochrane Database Syst Rev (4): CD000305. doi:10.1002/14651858.CD000305. PMID 12519540.
- Kusmer, Ken (20 September 2006). "3rd Ind. preemie infant dies of overdose". Fox News (Associated Press). Archived from the original on 18 October 2007. Retrieved 2007-01-08.
- Internal medicine, Jay H. Stein, page 635
- "Protamine Sulfate". The American Society of Health-System Pharmacists. Archived from the original on 6 November 2016. Retrieved 8 December 2016.
- Nader, H.B.; Chavante, S.F.; Dos-Santos, E.A.; Oliveira, F.W.; De-Paiva, J.F.; Jerônimo, S.M.B.; Medeiros, G.F.; De-Abreu, L.R.D.; et al. (1999). "Heparan sulfates and heparins: similar compounds performing the same functions in vertebrates and invertebrates?". Braz. J. Med. Biol. Res. 32 (5): 529–538. doi:10.1590/S0100-879X1999000500005. PMID 10412563.
- Cox, M.; Nelson D. (2004). Lehninger, Principles of Biochemistry. Freeman. p. 254. ISBN 0-7167-4339-6.
- Warda M, Mao W., et al. (2003). "Turkey intestine as a commercial source of heparin? Comparative structural studies of intestinal avian and mammalian glycosaminoglycans". Comp. Biochem. Physiol. B Biochem. Mol. Biol. 134 (1): 189–197. doi:10.1016/S1096-4959(02)00250-6. PMID 12524047.
- Ototani N, Kikuchi M, Yosizawa Z.; Kikuchi; Yosizawa (1981). "Comparative studies on the structures of highly active and relatively inactive forms of whale heparin". J Biochem. 90 (1): 241–246. PMID 7287679.
- Warda M, Gouda EM., et al. (2003). "Isolation and characterization of raw heparin from dromedary intestine: evaluation of a new source of pharmaceutical heparin". Comp. Biochem. Physiol. C Toxicol. Pharmacol. 136 (4): 357–365. doi:10.1016/j.cca.2003.10.009. PMID 15012907.
- Bland CE, Ginsburg H., et al. (1982). "Mouse heparin proteoglycan. Synthesis by mast cell-fibroblast monolayers during lymphocyte-dependent mast cell proliferation". J. Biol. Chem. 257 (15): 8661–8666. PMID 6807978.
- Linhardt RJ, Ampofo SA., et al. (1992). "Isolation and characterization of human heparin". Biochemistry. 31 (49): 12441–12445. doi:10.1021/bi00164a020. PMID 1463730.
- Hovingh P, Linker A.; Linker (1982). "An unusual heparan sulfate isolated from lobsters (Homarus americanus)". J. Biol. Chem. 257 (16): 9840–9844. PMID 6213614.
- Hovingh P, Linker A.; Linker (1993). "Glycosaminoglycans in Anodonta californiensis, a freshwater mussel". Biol. Bull. 185 (2): 263–276. doi:10.2307/1542006. JSTOR 1542006. Archived from the original on 2007-09-27.
- Pejler G, Danielsson A., et al. (1987). "Structure and antithrombin-binding properties of heparin isolated from the clams Anomalocardia brasiliana and Tivela mactroides". J. Biol. Chem. 262 (24): 11413–11421. PMID 3624220.
- Dietrich CP, Paiva JF., et al. (1999). "Structural features and anticoagulant activities of a novel natural low-molecular-weight heparin from the shrimp Penaeus brasiliensis". Biochim. Biophys. Acta. 1428 (2–3): 273–283. doi:10.1016/S0304-4165(99)00087-2. PMID 10434045.
- Medeiros GF, Mendes, A., et al. (2000). "Distribution of sulfated glycosaminoglycans in the animal kingdom: widespread occurrence of heparin-like compounds in invertebrates". Biochim. Biophys. Acta. 1475 (3): 287–294. doi:10.1016/S0304-4165(00)00079-9. PMID 10913828.
- Flengsrud R (2016). "Disaccharide analysis of chondroitin and heparin from farmed Atlantic salmon". Glycoconjugate Journal. 33 (2): 121–123. doi:10.1007/s10719-016-9652-8.
- Zhang F., Zhang Z., Thistle R., McKeen L.; et al. (2009). "Structural characterization of glycosaminoglycans from zebrafish in different ages". Glycoconj. Journal. 26 (2): 211–218. doi:10.1007/s10719-008-9177-x>.
- Hetzel, GR; et al. (2005), "The heparins: all a nephrologist should know", Nephrol Dial Transplant, 20 (10): 2036–2042, doi:10.1093/ndt/gfi004, PMID 16030035.
- Chuang YJ, Swanson R., et al. (2001). "Heparin enhances the specificity of antithrombin for thrombin and factor Xa independent of the reactive center loop sequence. Evidence for an exosite determinant of factor Xa specificity in heparin-activated antithrombin". J. Biol. Chem. 276 (18): 14961–14971. doi:10.1074/jbc.M011550200. PMID 11278930.
- Bjork I, Lindahl U.; Lindahl (1982). "Mechanism of the anticoagulant action of heparin". Mol. Cell. Biochem. 48 (3): 161–182. doi:10.1007/BF00421226. PMID 6757715.
- Herbert, Jean-Marc; Petitou, Maurice; Hérault, Jean-Pascal; Bernat, André; et al. (1999). "Synthesis of Thrombin inhibiting Heparin mimetics without side effects". Nature. 398 (6726): 417–422. doi:10.1038/18877. ISSN 0028-0836. PMID 10201371.
- Shalansky, Karen. DANAPAROID (Orgaran) for Heparin-Induced Thrombocytopenia. Archived 2007-09-28 at the Wayback Machine. Vancouver Hospital & Health Sciences Centre, February 1998 Drug & Therapeutics Newsletter. Retrieved on 8 January 2007.
- Eikelboom JW, Hankey GJ; Hankey (2002). "Low molecular weight heparins and heparinoids". The Medical Journal of Australia. 177 (7): 379–383. PMID 12358583. Archived from the original on 2011-09-09.
- Weitz JI (2004). "New anticoagulants for treatment of venous thromboembolism". Circulation. 110 (9 Suppl 1): I19–26. doi:10.1161/01.CIR.0000140901.04538.ae. PMID 15339877. Archived from the original on 2015-10-17.
- Hirsh, Jack; Raschke, Robert (September 2004). "Heparin and Low-Molecular-Weight Heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy". Chest. 126 (3): 188S–203S. doi:10.1378/chest.126.3_suppl.188S. PMID 15383472.
- Weitz DS, Weitz JI; Weitz (2010). "Update on heparin: what do we need to know?". Journal of Thrombosis and Thrombolysis. 29 (2): 199–207. doi:10.1007/s11239-009-0411-6. PMID 19882363.
- Francis CW, Kaplan KL (2006). "Chapter 21. Principles of Antithrombotic Therapy". In Lichtman MA, Beutler E, Kipps TJ, et al. Williams Hematology (7th ed.). ISBN 978-0-07-143591-8. Archived from the original on 2011-07-07.
- Bentolila, A.; et al. <377::AID-PAT985>3.0.CO;2-D/abstract "Synthesis and heparin-like biological activity of amino acid-based polymers". Polymers for Advanced Technologies. Wiley InterScience. 11: 377–387. doi:10.1002/1099-1581(200008/12)11:8/12<377::AID-PAT985>3.0.CO;2-D. Archived from the original on 2010-12-08. Retrieved 2008-03-10. (Subscription required (. ))
- Gatti, G.; Casu, B.; Hamer, G. K.; Perlin, A. S. (1979). "Studies on the Conformation of Heparin by1H and13C NMR Spectroscopy". Macromolecules. 12 (5): 1001–1007. doi:10.1021/ma60071a044. ISSN 0024-9297.
- "Online Medical Dictionary". Centre for Cancer Education. 2000. Archived from the original on 2007-08-13. Retrieved 2008-07-11.
- Ferro D, Provasoli A, et al. (1990). "Conformer populations of L-iduronic acid residues in glycosaminoglycan sequences". Carbohydr. Res. 195 (2): 157–167. doi:10.1016/0008-6215(90)84164-P. PMID 2331699.
- Mulloy B, Forster MJ, Jones C, Davies DB.; Forster; Jones; Davies (1 January 1993). "N.M.R. and molecular-modelling studies of the solution conformation of heparin". Biochem. J. 293 (Pt 3): 849–858. doi:10.1042/bj2930849. PMC . PMID 8352752.
- B. Mulloy, M.J. Forster. "N.M.R. and molecular-modeling studies of the solution conformation of heparin". Retrieved October 2016. Check date values in:
- Shaya D, Tocilj A., et al. (2006). "Crystal structure of heparinase II from Pedobacter heparinus and its complex with a disaccharide product". J. Biol. Chem. 281 (22): 15525–15535. doi:10.1074/jbc.M512055200. PMID 16565082.
- Galliher PM, Cooney CL., et al. (1981). "Heparinase production by Flavobacterium heparinum". Appl. Environ. Microbiol. 41 (2): 360–365. PMC . PMID 7235692.
- Linhardt RJ, Turnbull JE., et al. (1990). "Examination of the substrate specificity of heparin and heparan sulfate lyases". Biochemistry. 29 (10): 2611–2617. doi:10.1021/bi00462a026. PMID 2334685.
- Desai UR; Wang HM.; Linhardt RJ. (1993). "Specificity studies on the heparin lyases from Flavobacterium heparinum". Biochemistry. 32 (32): 8140–8145. doi:10.1021/bi00083a012. PMID 8347612.
- Linker A, Hovingh P.; Hovingh (1972). "Isolation and characterization of oligosaccharides obtained from heparin by the action of heparinase". Biochemistry. 11 (4): 563–568. doi:10.1021/bi00754a013. PMID 5062409.
- Linhardt RJ, Rice KG., et al. (1988). "Mapping and quantification of the major oligosaccharide components of heparin". Biochem. J. 254 (3): 781–787. PMC . PMID 3196292.
- Shively JE, Conrad HE.; Conrad (1976). "Formation of anhydrosugars in the chemical depolymerization of heparin". Biochemistry. 15 (18): 3932–3942. doi:10.1021/bi00663a005. PMID 9127.
- Hansen R, Koster A, Kukucka M, Mertzlufft F, Kuppe H (2000). "A quick anti-Xa-activity-based whole blood coagulation assay for monitoring unfractionated heparin during cardiopulmonary bypass: a pilot investigation". Anesth. Analg. 91 (3): 533–8. doi:10.1213/00000539-200009000-00006. PMID 10960371.
- R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 728-729.
- "Heparin used as an anticoagulant". AnimalResearch.info. Archived from the original on 2013-10-23.
- MCLEAN, J. (1 January 1959). "The Discovery of Heparin". Circulation. 19 (1): 75–78. doi:10.1161/01.CIR.19.1.75. PMID 13619023.
- Howell, W H. (1922). "Heparin, an anticoagulant". Am. J. Physiol. 63: 434–435.
- Mueller RL, Scheidt, S (1994). "History of drugs for thrombotic disease. Discovery, development, and directions for the future". Circulation. 89: 432–449. doi:10.1161/01.cir.89.1.432. PMID 8281678.
- Jorpes E (August 1935). "The chemistry of heparin". The Biochemical Journal. 29 (8): 1817–30. PMC . PMID 16745848.
- Rutty, CJ. "Miracle Blood Lubricant: Connaught and the Story of Heparin, 1928–1937". Health Heritage Research Services. Archived from the original on August 23, 2007. Retrieved 2007-05-21.
- Higgins, C. (October 2007). "The use of heparin in preparing samples for blood-gas analysis" (PDF). Medical Laboratory Observer.
- Yokota M, Tatsumi N, Nathalang O, Yamada T, Tsuda I.; Tatsumi; Nathalang; Yamada; Tsuda (1999). "Effects of Heparin on Polymerase Chain Reaction for Blood White Cells". J. Clin. Lab. Anal. 13 (3): 133–140. doi:10.1002/(SICI)1098-2825(1999)13:3<133::AID-JCLA8>3.0.CO;2-0. PMID 10323479.
- Xiong S, Zhang L, He QY (2008). "Fractionation of proteins by heparin chromatography". Methods Mol Biol. doi:10.1007/978-1-60327-064-9_18. PMID 18369865.
- "Affinity Chromatography". Sigma-Aldrich. Archived from the original on 2016-05-07.
- "HiTrap Heparin HP". GE Healthcare Life Sciences. Archived from the original on 2017-08-01.
- Guibinga GH, Miyanohara A, Esko JD, Friedmann T (May 2002). "Cell surface heparin sulfate is a receptor for attachment of envelope protein-free retrovirus-like particles and VSV-G pseudotyped MLV-derived retrovirus vectors to target cells". Mol Ther. 1 (5): 538–46. doi:10.1006/mthe.2002.0578. PMID 11991744. Archived from the original on 2017-09-10.
- Segura MM, Kamen A, Garnier A (2008). "Purification of retrovirus particles using heparin affinity chromatography". Methods Mol Biol (434): 1–11. doi:10.1007/978-1-60327-248-3_1. PMID 18470635. Archived from the original on 2017-09-10.
- Segura MM, Kamen A, trudel P, Garnier A (20 May 2005). "A novel purification strategy for tetrovirus gene therapy vectors using heparin affinity chromatography". Biotechnol Bioeng. 4 (90): 391–404. doi:10.1002/bit.20301. PMID 15812800. Archived from the original on 16 July 2016.
- Szabolcs Beni, John F. K. Limtiaco, Cynthia K. Larive; Limtiaco; Larive (September 2011). "Analysis and characterization of heparin impurities". Analytical and Bioanalytical Chemistry. 399 (2): 527–539. doi:10.1007/s00216-010-4121-x. PMC . PMID 20814668.
- AM2 PAT, Inc. Issues Nationwide Recall of Pre-Filled Heparin Lock Flush Solution USP (5 mL in 12 mL Syringes) Archived 2007-12-23 at the Wayback Machine., Am2pat, Inc. Press release, December 20, 2007[not in citation given]
- CBS News, Blood-thinning drug under suspicion Archived 2012-10-23 at the Wayback Machine.
- FDA informational page Archived 2012-04-15 at the Wayback Machine. with information and links about FDA investigation.
- Zawisza, Julie (29 March 2008). "FDA Media Briefing on Heparin" (PDF). U.S. Food and Drug Administration. Archived (PDF) from the original on 6 March 2010. Retrieved 2008-04-23.
- New York Times, March 6, 2008 Drug Tied to China Had Contaminant, F.D.A. Says, retrieved 2008-03-07
- New York Times, March 7, 2008 German Authorities Report Problems With Blood Thinner, retrieved 2008-03-07
- Blossom, DB; Kallen, AJ; Patel, PR; Elward, A; Robinson, L; Gao, G; Langer, R; Perkins, KM; et al. (2008). "Outbreak of adverse reactions associated with contaminated heparin". N Engl J Med. 359 (25): 2674–84. doi:10.1056/NEJMoa0806450. PMC . PMID 19052120.
- Nurse committed murders to "test" doctors Archived 2009-09-24 at the Wayback Machine., Radio Praha, May 12, 2006
- Ornstein, Charles; Gorman, Anna. (November 21, 2007) Los Angeles Times Report: Dennis Quaid's twins get accidental overdose. Archived March 7, 2008, at the Wayback Machine.
- Dennis Quaid and wife sue drug maker Archived 2010-06-28 at the Wayback Machine., USA Today, December 4, 2007
- Dennis Quaid files suit over drug mishap Archived 2008-07-04 at the Wayback Machine., Los Angeles Times, December 5, 2007
- Quaid Awarded $750,000 Over Hospital Negligence Archived 2009-04-15 at the Wayback Machine., SFGate.com, December 16, 2008
- WTHR story Archived 2011-06-29 at the Wayback Machine. about Methodist Hospital overdose
- Statement by Dr. Richard Davis, Chief Medical Officer, CHRISTUS Spohn Health System[permanent dead link], July 10, 2008
- At a Glance Heparin Overdose at Hospital Archived 2008-10-25 at the Wayback Machine., Dallas Morning News, July 11. 2008
- "Officials Investigate Infants' Heparin OD at Texas Hospital Archived 2008-07-11 at the Wayback Machine.." ABC News. July 11, 2008. Retrieved on July 24, 2008.
- "Heparin Overdose Kills Toddler At Hospital, Staff Investigated Archived 2012-03-20 at the Wayback Machine.." "KETV Omaha." March 31, 2010.
- Linhardt RJ, Gunay NS.; Gunay (1999). "Production and Chemical Processing of Low Molecular Weight Heparins". Sem. Thromb. Hem. 3: 5–16. PMID 10549711.
- Bhattacharya, Ananyo (August 2008). "Flask synthesis promises untainted heparin". Chemistry World. Royal Society of Chemistry. Archived from the original on 21 October 2012. Retrieved 6 February 2011.
- Xu, Y.; Masuko, S.; Takieddin, M.; Xu, H.; Liu, R.; Jing, J.; Mousa, S. A.; Linhardt, R. J.; Liu, J. (2011). "Chemoenzymatic Synthesis of Homogeneous Ultralow Molecular Weight Heparins". Science. 334 (6055): 498–501. doi:10.1126/science.1207478. PMC . PMID 22034431.
- Lever R.; Page C.P. (2002). "Novel drug opportunities for heparin". Nature Reviews Drug Discovery. 1 (2): 140–148. doi:10.1038/nrd724. PMID 12120095.
- Coombe D.R.; Kett W.C. (2005). "Heparan sulfate-protein interactions: therapeutic potential through structure-function insights". Cell. Mol. Life Sci. 62 (4): 410–424. doi:10.1007/s00018-004-4293-7. PMID 15719168.
- Baba M, Pauwels R, Balzarini J, Arnout J, Desmyter J, De Clercq E; Pauwels; Balzarini; Arnout; Desmyter; De Clercq (1988). "Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro". PNAS. 85 (16): 6132–6. Bibcode:1988PNAS...85.6132B. doi:10.1073/pnas.85.16.6132. PMC . PMID 2457906.
- Marcum JA (January 2000). "The origin of the dispute over the discovery of heparin". Journal of the History of Medicine and Allied Sciences. 55 (1): 37–66. doi:10.1093/jhmas/55.1.37. PMID 10734720.
- Mulloy B, Hogwood J, Gray E, Lever R, Page CP (January 2016). "Pharmacology of Heparin and Related Drugs". Pharmacological Reviews. 68: 76–141. doi:10.1124/pr.115.011247.